SCYNEXIS prices IPO at $10, as expected

Comment

Shutterstock photo

SCYNEXIS, a biotech developing treatments for life-threatening fungal infections, raised $62 million by offering 6.2 million shares at $10, as expected. SCYNEXIS plans to list on the NASDAQ under the symbol SCYX. RBC Capital Markets and Canaccord Genuity acted as joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com